BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 33438718)

  • 1. Post-marketing surveillance study of trifluridine/tipiracil in patients with metastatic colorectal cancer.
    Yoshino T; Uetake H; Funato Y; Yamaguchi Y; Koyama T; Ozawa D; Tajiri M; Muro K
    Jpn J Clin Oncol; 2021 Apr; 51(5):700-706. PubMed ID: 33438718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis.
    Basso M; Signorelli C; Calegari MA; Lucchetti J; Zurlo IV; Dell'Aquila E; Arrivi G; Zoratto F; Santamaria F; Saltarelli R; Trovato G; Caira G; Angotti L; Schirripa M; Anghelone A; Schietroma F; Chilelli MG; Salvatore L; Pozzo C; Tortora G
    Target Oncol; 2024 May; 19(3):371-382. PubMed ID: 38613732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trifluridine-tipiracil plus bevacizumab versus trifluridine-tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis.
    Aquino de Moraes FC; Dantas Leite Pessôa FD; Duarte de Castro Ribeiro CH; Rodrigues Fernandes M; Rodríguez Burbano RM; Carneiro Dos Santos NP
    BMC Cancer; 2024 Jun; 24(1):674. PubMed ID: 38825703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review.
    Shitara K; Falcone A; Fakih MG; George B; Sundar R; Ranjan S; Van Cutsem E
    Oncologist; 2024 May; 29(5):e601-e615. PubMed ID: 38366864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive significance of FGFR4 p.G388R polymorphism in metastatic colorectal cancer patients receiving trifluridine/tipiracil (TAS-102) treatment.
    Ottaiano A; Santorsola M; Ianniello M; Ceccarelli A; Casillo M; Sabbatino F; Petrillo N; Cascella M; Caraglia F; Picone C; Perri F; Sirica R; Zappavigna S; Nasti G; Savarese G; Caraglia M
    J Transl Med; 2024 Apr; 22(1):379. PubMed ID: 38650006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving survival in metastatic colorectal cancer through optimized patient selection.
    Bekaii-Saab TS; Barzi A; Cusnir M
    Clin Adv Hematol Oncol; 2024 Jun; 22 Suppl 4(5):1-20. PubMed ID: 38805297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequencing considerations in the third-line treatment of metastatic colorectal cancer.
    Barzi A; Bekaii-Saab T
    Am J Manag Care; 2024 May; 30(2 Suppl):S31-S35. PubMed ID: 38701364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting Trifluridine/Tipiracil Treatment Outcomes in Refractory Metastatic Colorectal Cancer Patients: A Multicenter Exploratory Analysis.
    Prejac J; Omrčen T; Radić J; Vrdoljak E; Fröbe A; Pleština S
    Oncology; 2024; 102(3):217-227. PubMed ID: 37699377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life in a real-world study of patients with metastatic colorectal cancer treated with trifluridine/tipiracil.
    Cheung WY; Kavan P; Dolley A
    Curr Oncol; 2020 Oct; 27(5):e451-e458. PubMed ID: 33173384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging emetogenicity of trifluridine/tipiracil (TAS‑102) from patient self-reporting: a multicenter, prospective, observational study.
    Fujii H; Tsuchiya M; Watanabe D; Otsuka R; Hirate D; Takahashi K; Go M; Kudo T; Shimomura K; Ando Y; Tani S; Takahashi T; Hayashi K; Chin M; Matsunami N; Takahashi M; Hasegawa A; Uchida T; Hashimoto H; Kubo A; Matsuhashi N; Suzuki A; Nishimura J; Inui N; Iihara H
    Support Care Cancer; 2024 Apr; 32(5):291. PubMed ID: 38630197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delphi consensus for the third-line treatment of metastatic colorectal cancer.
    García-Alfonso P; Vera R; Aranda E; Élez E; Rivera F
    Clin Transl Oncol; 2024 Jun; 26(6):1429-1437. PubMed ID: 38411748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer-single institutional experience.
    Okunaka M; Kawazoe A; Nakamura H; Kotani D; Mishima S; Kuboki Y; Nakamura Y; Shitara K
    Gastric Cancer; 2023 Nov; 26(6):1030-1039. PubMed ID: 37665515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of previous treatment as a prognostic factor in metastatic colorectal cancer treated with trifluridine/tipiracil.
    Skuja E; Gerina-Berzina A; Hegmane A; Zvirbule Z; Vecvagare E; Purkalne G
    Mol Clin Oncol; 2018 May; 8(5):699-702. PubMed ID: 29725539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Japanese post-marketing surveillance of cetuximab (Erbitux®) in patients with metastatic colorectal cancer.
    Ishiguro M; Watanabe T; Yamaguchi K; Satoh T; Ito H; Seriu T; Sakata Y; Sugihara K
    Jpn J Clin Oncol; 2012 Apr; 42(4):287-94. PubMed ID: 22327124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative Analysis of the Concentration of Trifluridine in Tumor Hypoxic Regions Using a Novel Platform Combining Functional Endoscopy and Mass Spectrometry.
    Koganemaru S; Fuchigami H; Yamashita H; Morizono C; Sunakawa H; Kawazoe A; Nakamura Y; Kuboki Y; Shitara K; Yano T; Doi T; Yasunaga M
    Clin Pharmacol Ther; 2024 Jan; 115(1):62-70. PubMed ID: 37803526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer.
    Raedler LA
    Am Health Drug Benefits; 2016 Mar; 9(Spec Feature):97-100. PubMed ID: 27668054
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug Monographs: Trabectedin and Trifluridine-Tipiracil.
    Solimando DA; Waddell JA
    Hosp Pharm; 2016 Feb; 51(2):120-128. PubMed ID: 38746764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer.
    Yamaguchi K; Fuse N; Komatsu Y; Fujii H; Hironaka S; Omuro Y; Muro K; Yasui H; Ueda S; Nishina T; Watanabe M; Ohtsu A
    Jpn J Clin Oncol; 2021 May; 51(6):879-885. PubMed ID: 33561262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial.
    Kawazoe A; Ando T; Hosaka H; Fujita J; Koeda K; Nishikawa K; Amagai K; Fujitani K; Ogata K; Watanabe K; Yamamoto Y; Shitara K
    Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):209-217. PubMed ID: 33508242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Case Series of the TAS-102 plus Bevacizumab(Bev)Combination Therapy in Unresectable Advanced Colorectal Cancer].
    Naito A; Iwamoto K; Ohtsuka M; Imasato M; Inui M; Zenitani S; Wada R; Nakahara Y; Mikamori M; Furukawa K; Moon J; Asaoka T; Kishi K; Akamatsu H
    Gan To Kagaku Ryoho; 2020 Dec; 47(13):2104-2106. PubMed ID: 33468875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.